Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

d test model, (xiv) our ability to timely capitalize on any increases in market demand, (xv) increased costs related to downsizing and compliance with regulatory compliance in connection with such downsizing, (xvi) competition and pricing pressure, (xvii) the potential lack of availability of credit or opportunity for equity based financing, (xviii) the risks associated with our international operations, (xix) the outcome of tax audits or similar proceedings, (xx) the outcome of pending litigation against the company, (xxi) our ability to maintain or increase our cash reserves and obtain financing on terms acceptable to us, and (xxii) other factors described in Oclaro's most recent annual report on Form 10-K, quarterly report on Form 10-Q and other documents we periodically file with the SEC. The forward-looking statements included in this announcement represent Oclaro's view as of the date of this announcement. Oclaro anticipates that subsequent events and developments may cause Oclaro's views and expectations to change. Oclaro specifically disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.

Non-GAAP Financial MeasuresOclaro provides certain supplemental non-GAAP financial measures to its investors as a complement to the most comparable GAAP measures. The GAAP measure most directly comparable to non-GAAP gross margin rate is gross margin rate. The GAAP measure most directly comparable to non-GAAP operating income/loss is operating income/loss. The GAAP measure most directly comparable to non-GAAP net income/loss and Adjusted EBITDA is net income/loss. An explanation and reconciliation of each of these non-GAAP financial measures to GAAP information is set forth below.

Oclaro believes that providing these non-GAAP measures to its investors, in addition to corresponding income statement measures, provides investor
'/>"/>

SOURCE Oclaro, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
8. Kemwell Announces Successful Pre-NDA US FDA Inspection
9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... CARLSBAD, Calif. , Aug. 3, 2015 /PRNewswire/ ... AstraZeneca today announced a strategic collaboration to discover ... renal diseases. The new collaboration builds on a ... supports AstraZeneca,s strategic approach in these therapeutic areas ... Pharmaceuticals to extend use of its antisense technology ...
(Date:8/2/2015)... , August 3, 2015 Mandatory ... Dechra Pharmaceuticals PLC ("Dechra" or the "Company") is pleased ... agreement ("SPA") with Mr. Marijan Han žeković to ... in Genera d.d. ("Genera"), a Croatian listed pharmaceutical business. ... share, which is equivalent to €51.4 million for the ...
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. ... pivotal TELESTAR Phase 3 clinical trial met its ... etiprate in treating cancer patients with carcinoid syndrome ... standard of care. Telotristat etiprate was discovered using ... and is the company,s first discovery to complete ...
Breaking Medicine Technology:AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... , RARITAN, N.J., Dec. 30 Johnson & ... it received a Complete Response letter from the U.S. ... Drug Application (NDA) was originally submitted to the FDA ... and skin structure infections (cSSSI), including diabetic foot infections. ...
... 29 A Pennsylvania-based company has just released a ... to the App Store. , David Warden, who ... an application called i-Inject that allows fellow patients to ... place for users to track their rotation of injection ...
Cached Medicine Technology:FDA Issues Complete Response Letter for Ceftobiprole 2iPhone Application Designed for Multiple Sclerosis Patients is Launched 2
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director ... August. The new facility is licensed under Dignity Health Arizona General Hospital ... is an excellent leader and will ensure our new freestanding emergency room delivers the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Hub International Insurance ... Williams has joined its growing California employee benefits division. Mr. Williams will ... his clients. Mr. Williams will be joining the newly integrated Northern California employee ...
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from ... tissue injury caused by diabetes after many years of suffering and using medications with ... he didn’t want to ask for extra time off or wait longer hours in ...
(Date:8/3/2015)... ... August 03, 2015 , ... Cambia Health Solutions has promoted ... the company’s Medicare and Federal Employee Programs (FEP) lines of business. , ... for members. In this role, Scott is responsible for overseeing the growth, finance ...
(Date:8/3/2015)... ... 03, 2015 , ... Foot and Ankle Specialists of the Mid-Atlantic (FASMA) ... largest medical practice in the Mid-Atlantic region – and the second largest in the ... 33 doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland native. She grew up in ...
Breaking Medicine News(10 mins):Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4
... specialists from all over the world will meet at Mount ... heart disease in India and how preventive measures can help ... on Clinical & Preventive Cardiology is being held from September ... for several burning issues and newer technologies besides crystallizing recent ...
... recent clinical trials of inhaled insulin has received the approval ... in regulating blood sugar levels spanning a 2 year period. ... introduced into the United States market soon after the U.S. ... with Type 1 or Type 2 diabetes. ,Dr. Julio ...
... said that the breast cancer drug Herceptin was approved to be ... happy news to the grieving family of Tamar Bailey. //She is ... denied her the drug which led to her early death. She ... was an advertising art director from Wimbledon, south-west London. She had ...
... National Institute of Standards and Technology (NIST) researchers have ... of complex surfaces, which vary in a controlled fashion ... is so flexible that it can be applied to ... exploring the bonding of proteins to cell membranes. ...
... first spacewalk was successfully by two crewmen in the early ... jobs on the international space station within 6.5 hours on ... 8 hours and 56 minutes. Except for a video camera ... placed on a transport platform. ,After Russians have ...
... - high school and college students are now co-authors in ... of 30 macrophages has been made possible by digging in ... 9, 2006 has a report of a research team lead ... The report is about the characterization and cataloguing of genomes ...
Cached Medicine News:Health News:World Cong On Preventive Cardiology In Sept 2Health News:New Technique For Science Experiments 2
... This stool is unquestionably the finest operating room ... for the ophthalmic surgeon who must remain ... poor stool can unexpectedly shift resulting in unanticipated ... base of five sturdy casters. A "foot bar" ...
... The Multi-Cap system provides patients ... from distance viewing to reading. ... 1.75x for distance viewing. The ... 2x, 3x and 4x magnifications. ...
... The Wide-Vu magnifier is ... telescope for reading. It ... view than the LVA21 and ... distance. The Wide-Vu can be ...
... takes us to the practical limit ... is often a 'last resort' option ... acuities. The illuminated housing ensures a ... the battery handle by a lightweight ...
Medicine Products: